Table 1. Summary of immunoreactive variations between N1-8 monoclonal and polyclonal antibodies in a series of 57 clinical breast cancer cases.

			N1-8 monoclonal
		(−)		(+)	Cases
		cytoplasm
		(−)	(+)
N1-polyclonal
	cytoplasm
(−)	(−)	4	5	0	9
	(+)	2	8	0	10	19
(+)		0	0	38		38
		6	13
			19	38		57

Although N1-8 could recognize cytoplasmic RB1CC1 better than the polyclonal antibody (13 vs 10 cases), both antibodies were completely consistent in recognizing the nuclear reactivity of RB1CC1.